

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Kennedy Lawrence T. Jr</u> (Last) (First) (Middle) 1700 MADISON ROAD, SUITE 200 (Street) CINCINNATI OH 45206 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIODESIX INC [BDSX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 01/03/2023	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Units	(1)	01/03/2023		A		91,463		(2)	(2)	Common Stock	91,463	\$0	91,463 ⁽⁴⁾	D	
Restricted Stock Units	(1)	01/03/2023		A		27,408		(3)	(3)	Common Stock	27,408	\$0	27,408 ⁽⁴⁾	D	
Stock Options (Right to Buy)	\$2.05	01/03/2023		A		124,998		(5)	01/02/2033	Common Stock	124,998	\$0	124,998	D	

Explanation of Responses:

- Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer common stock.
- These RSUs will vest in full on January 3, 2024, generally subject to the Reporting Person's continued service on the Issuer's board of directors (the "Board") through the applicable vesting date, and have no expiration date.
- These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service on the Board through the applicable vesting date, and have no expiration date.
- Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer.
- This option vests 40% on January 3, 2025, and the remaining 60% in 36 successive, equal monthly installments measured from January 3, 2025, generally subject to the Reporting Person's continued service on the Board through the applicable vesting date.

/s/ Robin H. Cowie as Attorney-in-Fact for Lawrence T. Kennedy, Jr. 01/05/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.